Cargando…
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Type 2 diabetes affects more than 350 million people worldwide, and its prevalence is increasing. Many patients with diabetes do not achieve and/or maintain glycemic targets, despite therapy implementation and escalation. Multiple therapeutic classes of agents are available for the treatment of type...
Autores principales: | Salvo, Marissa C, Brooks, Amie D, Thacker, Stacey M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003262/ https://www.ncbi.nlm.nih.gov/pubmed/24790417 http://dx.doi.org/10.2147/PPA.S59169 |
Ejemplares similares
-
Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker, Catherine M, et al.
Publicado: (2016) -
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010) -
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019) -
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)